{"organizations": [], "uuid": "a8ede2a3676e590141db911dcbf344f5a5fd0bec", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180308.html", "section_title": "Archive News &amp; Video for Thursday, 08 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-invivo-therapeutics-receives-fda-a/brief-invivo-therapeutics-receives-fda-approval-for-controlled-trial-of-the-neuro-spinal-scaffold-idUSASB0C9FI", "country": "US", "domain_rank": 408, "title": "BRIEF-Invivo Therapeutics Receives FDA Approval For Controlled Trial Of The Neuro-Spinal Scaffold™", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.389, "site_type": "news", "published": "2018-03-08T21:18:00.000+02:00", "replies_count": 0, "uuid": "a8ede2a3676e590141db911dcbf344f5a5fd0bec"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-invivo-therapeutics-receives-fda-a/brief-invivo-therapeutics-receives-fda-approval-for-controlled-trial-of-the-neuro-spinal-scaffold-idUSASB0C9FI", "ord_in_thread": 0, "title": "BRIEF-Invivo Therapeutics Receives FDA Approval For Controlled Trial Of The Neuro-Spinal Scaffold™", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "invivo therapeutics holdings corp", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 8 (Reuters) - Invivo Therapeutics Holdings Corp :\n* INVIVO THERAPEUTICS RECEIVES FDA APPROVAL FOR PIVOTAL, RANDOMIZED, CONTROLLED TRIAL OF THE NEURO-SPINAL SCAFFOLD™ IN PATIENTS WITH ACUTE SPINAL CORD INJURY Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-08T21:18:00.000+02:00", "crawled": "2018-03-09T14:54:35.007+02:00", "highlightTitle": ""}